Trial Profile
A multicentre, open-label, observational local study to evaluate the LDL [low density lipoprotein]-C lowering effect of ezetimibe as prescribed in daily routine practice in the South African population
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Organon
- 14 Jun 2007 New trial record.